Clinical trials: Carcinoma of Prostate (Disorder)
Prostate Cancer
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
The overarching goal is to prospectively recruit men considering active surveillance for treatment in the MAGIC (MRI And GPS Informing Choices for prostate cancer treatment) Cohort to provide meaningful data on active…
- Trial name
- MAGIC (NCT05424783)
- Testing
- Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate
- Where
- 2 sites in United States
- Volunteers
- 222 people
- Sponsor
- Northwestern University
Prostate Cancer
Radioligand fOr locAl raDiorecurrent proStaTe cancER
Approximately 50-60% of men undergoing salvage brachytherapy post cancer recurrence to the prostate have the disease controlled at 5 years.
- Trial name
- ROADSTER (NCT05230251)
- Testing
- 177Lu-PNT2002, High Dose Radiation
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Glenn Bauman
Prostate Cancer
Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects
Primary Goal The study's primary goal is to assess the safety of the BioProtect biodegradable balloon implant and implantation procedure, in prostate cancer subjects undergoing routine radiation therapy (XRT) treatment.
- Trial name
- NCT00918229
- Testing
- balloon implant, Balloon implantation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- BioProtect
Prostate Cancer
Radioactive Counts From PSMA PET/CT-Targeted Biopsy Specimens for Real-time Diagnosis of Prostate Cancer: A Prospective Study
This study aims to establish the diagnostic threshold and efficacy of radioactive counts (CPM) from biopsy specimens in distinguishing cancer-containing from non-cancer-containing cores, using prostate biopsy pathology as the…
- Trial name
- NCT07709403
- Testing
- No intervention (observational study)
- Volunteers
- 20 people
- Sponsor
- Peking University First Hospital
Prostatic Neoplasms, Adenocarcinoma
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose…
- Trial name
- NCT04644770
- Testing
- JNJ-69086420, JNJ-78278343, Stereotactic body radiation therapy
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Prostate Cancer, Prostate Cancer
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic…
- Trial name
- NCT07145177
- Testing
- 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite…
- Trial name
- NCT06705803
- Testing
- Prostate Ablation
- Where
- 2 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- University of Chicago
Breast Cancer, Ovarian Cancer
OPTimizing Treatment Focused Genetic Testing IN Cancer
This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- OPT-IN (NCT04066361)
- Testing
- Chatbot, Video Education
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Erectile Dysfunction
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
The purpose of this study is to test two different ways to help men with sexual rehabilitation.
- Trial name
- NCT02706561
- Testing
- questionnaires, three in-person sessions, monthly phone calls
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Prostate Disease
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
The purpose of this study is to test the safety, tolerability, and effectiveness of the investigational drug nivolumab (Opdivo™) in combination with high dose radiation.
- Trial name
- NCT03543189
- Testing
- Nivolumab, Brachytherapy, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
Prostate Cancer (PC) is the most frequent cancer in men, accounting for 21% of new cases of cancer in men in the United States. Among the four most incident tumors (breast, lung and colorectal cancer); prostate cancer is the only…
- Trial name
- ImmunoProst (NCT03040791)
- Testing
- Nivolumab
- Where
- 2 sites in Brazil
- Volunteers
- 38 people
- Sponsor
- Hospital Moinhos de Vento
Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05828082
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Hormone Refractory Prostate Cancer
Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
This investigational study involves treatment with an Ad/PSA vaccine for men with prostate cancer who present with evidence of hormone refractory metastatic disease.
- Trial name
- APP22 (NCT00583024)
- Testing
- ADENOVIRUS/PSA VACCINE
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- David M Lubaroff
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic…
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01270880
- Testing
- Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer
As the most common carcinoma in men, prostate cancer is a significant tumor entity in oncology. In addition to the surgical approach, definitive radiotherapy is an equivalent therapy alternative in the non-metastatic primary…
- Trial name
- SMILE (NCT04845503)
- Testing
- MR-guided Radiotherapy
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- University Hospital Heidelberg
Prostate Cancer
Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)
This study aims to evaluate the role of PSMA-PET and circulating tumor DNA (ctDNA) in monitoring prostate cancer progression and response to radiotherapy (RT).
- Trial name
- NCT07210086
- Testing
- ADT, ARSI, No ADT/ARSI -decline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- City of Hope Medical Center
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate…
- Trial name
- NCT06136650
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone acetate
- Where
- 330 sites in United States, Australia and 37 more
- Volunteers
- 1,314 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
This study tests the safety and tolerability of autologous anti-PSMA gene-modified T cells (designer T cells) in hormone refractory prostate cancer.
- Trial name
- NCT00664196
- Testing
- Gene Modified T Cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roger Williams Medical Center
Prostate Cancer
Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
Prostate cancer is the most common cancer among men in the United States. Through early detection and improved local therapies a large number of men will be cured.
- Trial name
- NCT01417182
- Testing
- 18F-DCFBC
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who…
- Trial name
- NCT02384382
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.